Selective T Cell Costimulation Blocker [EPC]

4739 reported adverse events

Drugs of this class: BELATACEPT

These side effects are most commonly reported by patients taking drugs of the Selective T Cell Costimulation Blocker [EPC] class:

# Side effect Count
0 OFF LABEL USE 463
1 DEATH 232
2 TRANSPLANT REJECTION 231
3 KIDNEY TRANSPLANT REJECTION 222
4 DRUG INEFFECTIVE 196
5 CYTOMEGALOVIRUS INFECTION 179
6 ACUTE KIDNEY INJURY 178
7 PRODUCT STORAGE ERROR 177
8 COVID-19 149
9 HOSPITALISATION 128
See all common reactions for Selective T Cell Costimulation Blocker [EPC]

Drugs of the Selective T Cell Costimulation Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 OTITIS EXTERNA CANDIDA 2 0.2222
1 ENTEROCOLITIS FUNGAL 6 0.2000
2 HERPES SIMPLEX MENINGITIS 9 0.1268
3 INFERIOR VENA CAVA STENOSIS 6 0.1224
4 KAPOSI SARCOMA INFLAMMATORY CYTOKINE SYNDROME 7 0.1186
5 EPIGLOTTIC ERYTHEMA 2 0.1111
6 IMMUNOSUPPRESSANT DRUG LEVEL 3 0.1000
7 MYCOBACTERIUM HAEMOPHILUM INFECTION 28 0.0979
8 DIFFUSE MESANGIAL SCLEROSIS 3 0.0968
9 REMOVAL OF RENAL TRANSPLANT 4 0.0909
See all enriched reactions for Selective T Cell Costimulation Blocker [EPC]